Basic Principles for Calculating the Required Number of Participants in Clinical Trials. Part 2. Survival Analysis (Review)

INTRODUCTION. Survival analysis is an important biostatistics method used in clinical trials to confirm the long-term efficacy and safety of medicinal products. The significance of this method lies in the possibility to extrapolate the conclusion regarding the benefits of a medical intervention drawn from a short-term clinical trial to a longer period and adjust dosages and treatment regimens accordingly. However, comprehensive methodological recommendations for planning survival analyses are currently lacking.

AIM. This study aimed to systematise the requirements for sample size calculation in event-based study designs.

DISCUSSION. This article presents methods for calculating the number of subjects required for survival analysis in event-driven studies with outcome collection and estimation under censoring conditions. The authors discuss Bayesian probabilistic models for estimating survival parameters, such as the time to an event, the risk of an event, and the cumulative survival rate, as key variables for determining the sample size for a study. The article presents a theoretical framework for event risk analysis in survival study designs. The authors describe hypotheses and sta­tistical models for calculating sample sizes and determining survival parameter thresholds in group sequential designs for event risk studies.

CONCLUSIONS. The statistical models presented can be used to design studies aimed at estimating the time to an expected event and the cumulative risk during treatment and following medicinal product administration.

1. Shreder OV, Goryachev DV, Merkulov VA. Basic principles for calculating the required number of participants in clinical trials. Part 1. Common approaches (review). Regulatory Research and Medicine Evaluation. 2024;14(3):338–50 (In Russ.). https://doi.org/10.30895/1991-2919-2024-14-3-338-350

2. Thabane L. Sample size determination in clinical trials. HRM-733 Class Notes. Hamilton: St. Joseph’s Healthcare; 2004.

3. Matthews JN. An introduction to randomized controlled clinical trials. New York: Chapman & Hall; 2006. https://doi.org/10.1201/9781420011302

4. Lindley DV. A statistical paradox. Biometrika. 1957;44:187–92. https://doi.org/10.1093/biomet/44.1-2.187

5. Gittins J, Pezeshk H. A behavioral Bayes method for determining the size of a clinical trial. Ther Innov Regul Sci. 2000;34:355–63. https://doi.org/10.1177/009286150003400204

6. Gittins J, Pezeshk H. How large should a clinical trial be? J R Stat Soc Ser D Stat. 2000;49(2):177–87. https://doi.org/10.1111/1467-9884.00228

7. O’Hagan A, Stevens JW, Campbell MJ. Assurance in clinical trial design. Pharm Stat. 2005;4(3):187–201. https://doi.org/10.1002/pst.175

8. Shreder OV, Bunyatyan ND, Goryachev DV, Subaev RD, Engalycheva GN, Kuznetsova AD, Kosenko VV. Mathema-tical prediction of the efficacy of medicinal products in preclinical studies. Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation. 2022;12(3):315–30 (In Russ.). https://doi.org/10.30895/1991-2919-2022-12-3-315-330

9. Machin D, Campbell M, Fayers P, Pinol A. Sample size tables for clinical studies. Malden, MA: Blackwell Science; 2008. https://doi.org/10.1002/9781444300710.ch3

10. Chow SC, Shao J, Wang H, Lokhnygina Y. Sample size calculations in clinical research. New York: Marcel Dekker; 2017. https://doi.org/10.1080/24754269.2017.1398000

11. Gordon Lan KК, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70(3):659–63. https://doi.org/10.1093/biomet/70.3.659

12. O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549–56. PMID: 497341

13. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64(2):191–9. https://doi.org/10.1093/biomet/64.2.191

14. Reboussin DM, DeMets DL, Kim K, Gordon Lan KK. Computations for group sequential boundaries using the Lan–DeMets spending function method. Control Clin Trials. 2000;21(3):190–207. https://doi.org/10.1016/S0197-2456(00)00057-X

15. Glantz S. Medico-biological statistics. Moscow: Praktika; 1998 (In Russ.).

16. Zulkarnaev AB. Features of survival analysis on patients on the “waiting list” for kidney transplantation. Bulletin of Siberian Medicine. 2019;18(2):215–22 (In Russ.). https://doi.org/10.20538/1682-0363-2019-2-215-222

17. Motrenko AP. Estimation of the necessary patient sample size in predicting cardiovascular diseases. Journal of Machine Learning and Data Analysis. 2012;1(3):354–66 (In Russ.). EDN: OXWKKF

18. Kulikov SM, Parovichnikova EN, Savchenko VG. Survival or time-to-event analysis: Common pitfalls of retrospective approach. Clinical Oncohematology. Basic Research and Clinical Practice. 2010;3(2):176–83 (In Russ.). EDN: MWJXMB

19. Jiang Z, Wang L, Li C, Xia J, Jia H. A practical simulation method to calculate sample size of group sequential trials for time-to-event data under exponential and Weibull distribution. PLoS One. 2012;7(9):e44013. https://doi.org/10.1371/journal.pone.0044013

20. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 1986;42(3):507–19. PMID: 3567285

21. Shulika YuE. Survival analysis for authoritarian regimes in resource rent economies: Possibilities and limitations of the proportional hazards model. Bulletin of Perm University. Political Science. 2018;12(4):122–39 (In Russ.). https://doi.org/10.17072/2218-1067-2018-4-122-139

22. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials. 2000;21(6):552–60. https://doi.org/10.1016/S0197-2456(00)00104-5

23. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39(2):499–503. PMID: 6354290